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Abstract
One target of protective immunity against the Plasmodium liver stage in BALB/c mice is represented by the
circumsporozoite protein (CSP), and mainly involves its recognition by IFN-c producing specific CD8+T-cells. In a previous
in vitro study we showed that primary hepatocytes from BALB/c mice process Plasmodium berghei (Pb) CSP (PbCSP) and
present CSP-derived peptides to specific H-2kd restricted CD8+T-cells with subsequent killing of the presenting cells. We
now extend these observations to an in vivo infection model in which infected hepatocytes and antigen specific T-cell
clones are transferred into recipient mice inducing protection from sporozoite (SPZ) challenge. In addition, using a similar
protocol, we suggest the capacity of hepatocytes in priming of naı¨ve T-cells to provide protection, as further confirmed by
induction of protection after depletion of cross-presenting dendritic cells (DCs) by cytochrome c (cyt c) treatment or using
traversal deficient parasites. Our results clearly show that hepatocytes present Plasmodium CSP to specific-primed CD8+T-
cells, and could also prime naı¨ve T-cells, leading to protection from infection. These results could contribute to a better
understanding of liver stage immune response and design of malaria vaccines.
Citation: Balam S, Romero JF, Bongfen SE, Guillaume P, Corradin G (2012) CSP—A Model for In Vivo Presentation of Plasmodium berghei Sporozoite Antigens by
Hepatocytes. PLoS ONE 7(12): e51875. doi:10.1371/journal.pone.0051875
Editor: Anne Charlotte Gruner, Museum National d’Histoire Naturelle, France
Received May 30, 2012; Accepted November 8, 2012; Published December 18, 2012
Copyright:  2012 Balam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: giampietro.corradin@unil.ch
¤a Current address: EPFL SB IPSB LIFMET Station 6, Lausanne, Switzerland
¤b Current address: Department of Biochemistry, McGill University, Montreal, Quebec, Canada
. These authors contributed equally to this work.
Introduction
Immunization of rodents and humans with radiation- or
genetically-attenuated sporozoites (SPZ) (RAS, GAS) confers pre-
erythrocytic stage specific protective immunity to an infectious
challenge [1,2]. This protective immunity is mediated in part by
CD8+ T-cells specific for the CSP and other not yet identified
proteins [2–5]. Recently, it was demonstrated that both infected
and sporozoite-traversed mouse primary hepatocytes can process
the PbCSP and present CSP-derived peptides to a specific H-2Kd-
restricted CD8+ T-cell clone in vitro but recognition of infected
hepatocytes was the only relevant step in the elimination of
infection [6]. Using bone marrow cell transfer into totally
irradiated mice, it was also concluded that activation of protective
CD8+ T-cell clones was due to antigen presentation by
nonhematopoietic parenchymal cells [7]. Thus, the role of
hepatocytes as antigen presenting cells (APCs) in the activation
of primed T-cells to provide sterile protection seems to be
accepted. Nevertheless, the role of liver cells and, in particular,
hepatocytes in the activation of Plasmodium-specific CD8+ T-cells is
not clearly elucidated. Chakravarty et al. [7] presented data
supporting the role of lymph node dentritic cells (DCs) in
presentation to parasite-specific T-cells while Leiriao et al. [8]
supported the notion that apoptotic Plasmodium-infected hepato-
cytes provide antigen to liver DCs. While both pathways of antigen
presentation co-exist, their role in providing a protective CD8+ T-
cell response has not been established. In both studies, critical
experiments such as the elimination of DCs and its consequence
on sterile protection are missing. On the other hand, several
publications point to the role of liver cells and hepatocytes in the
mechanism of protection [2,5,9–11]. In addition, intravenous (iv)
injection in mice of RAS gives rise to a more robust immune
response and to sterile immunity compared to intradermal (id)
immunization [12]. On the other hand, this difference in
protection between iv and id injection is overcome by a higher
dose of sporozoites [13]. Furthermore, immunization of mice with
GAS is associated with a better immune response, probably due to
the development of GAS liver stages and presentation of antigens
other than CSP to specific T-cells [14].
It has been shown that CD8+ T-cells are primed by the DCs in
the skin, and are then thought to exit the priming site and migrate
to the liver where they can eliminate infection after recognizing
antigens presented by hepatocytes [2,7,9,15]. Thus, it was
concluded that initiation of the CD8+ T-cell mediated immunity
requires antigen presentation by only DCs [16]. On the other
hand, the infected hepatocyte is the cell where SPZs develop and
proliferate into the next liver forms. Furthermore, infection of
hepatocytes is crucial for maintenance of anti- SPZ protective
CD8+ T-cell response since protection was abrogated if hepatic
stages were eliminated [2,9,15]. However, the ability of hepato-
cytes to prime naı¨ve CD8+ T-cells and induce protective
immunity remains unclear. It has also been illustrated that
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hepatocytes present CSP that is secreted directly into the cytosol,
unlike DCs that cross-present Plasmodium antigens via endosomes
[16]. These findings suggested that both in DCs and hepatocytes,
the presentation of antigens requires the transporter associated
with antigen processing (TAP) proteins [16–18] and that the cross-
presenting DCs could be abrogated in mice after treatment with
cytochrome c (cyt c) [16]. Determining if hepatocytes in vivo
process and present Plasmodium antigens to naı¨ve and primed T-
cells may help in the rational identification of pre-erythrocytic
vaccine candidates. To this purpose, we have established an in vivo
protocol to address two questions: are hepatocytes capable of 1)
in vivo stimulation of primed CD8+ T-cells and 2) priming naı¨ve T-
cells to protect mice against parasite challenge? We used different
methods to address these two questions. First, we used intrasplenic
(IS) transfer of PbSPZ-infected hepatocytes from BALB/c mice
into naı¨ve, TAP2/2 deficient mice (H-2Kb) and BALB/c mice
(H-2Kd) in the presence or absence of H-2Kd-specific CD8+ T-
cells (C7 clone) in order to determine the ability of primary
hepatocytes to present antigen to primed CD8+ T-cells. Secondly,
to show that hepatocytes could present antigen in the absence of
dendritic cells, mice treated with cyt c were injected with irradiated
SPZ (iSPZ) and challenged with live SPZ. Thirdly, mice were
immunized with iSPZs deficient for the sporozoite microneme
protein essential for cell traversal (spect (2) iSPZs), known for being
incapable of cell traversal, but capable of infection and normal
development [6,19,20] in order to show the role of infected
hepatocytes in inducing a protective immune response. In all cases,
mice were partially or totally protected from an infectious SPZ
challenge as assessed by their level of blood parasitemia up to
14 days post infection.
Materials and Methods
Peptides
Peptides PbCS245–253 (YIPSAEKI) and PbCS253–260 modified
with iodo-azidosalicylic acid (IASA) and azidobenzoic acid (ABA)
groups, (IASA)-YIPSAEK(ABA)I representing the epitope for C7
clone (H-2Kd-restricted and PbCSP specific CTL) and S14 (H-
2Kd-restricted and an irrelevant CTL), respectively [3,21], were
synthesized by solid-phase F-moc chemistry. Peptide stock
solutions (2 mg/ml) were prepared in PBS and stored at 220uC.
Parasites
Plasmodium berghei ANKA wild-type (wt) and spect (2) SPZ were
obtained after salivary gland dissection of infected female Anopheles
stephensi mosquitos raised in the mosquito facility at the Depart-
ment of Biochemistry, University of Lausanne, Switzerland as
described previously [6,20]. After dissection, salivary glands were
homogenized in a glass grinder and released SPZ were counted
and then diluted in sterile Dulbecco’s Modified Eagle Medium,
DMEM (GibcoH, Life TechnologiesTM, New York, NY).
Animals
Six-to-12-week-old BALB/c (H-2Kd) or TAP2/2 (H-2Kb)
mice were obtained from Harlan Laboratories B.V. (Venray,
Netherlands) or bred at the animal facility at the Department of
Biochemistry (University of Lausanne, Switzerland). All mice were
housed under pathogen-free conditions and handled according to
the guidelines of the authorization Nu 805.7 of the Service de la
consommation et des affaires ve´te´rinaires (Lausanne, Switzerland).
Hepatocyte Isolation
SPZ-infected and naı¨ve hepatocytes from BALB/c mice were
obtained after collagenase perfusion of the liver as previously
described [6,20,22]. Briefly, mice were sacrificed by CO2
inhalation, dissected, and the biggest lobule of liver was cut out.
The lobule was perfused for 10 min with Ca2+-free HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, pH 7.6
(GibcoH InvitrogenTM, New York, NY) at 37uC at a rate of
5 ml/min. The lobule was then perfused with type IV collagenase
(Sigma-AldrichH, Steinheim, Germany) (HEPES buffer containing
0.04% type IV collagenase and 0.075% CaCl2-2H2O) for 5 min at
37uC. The perfused lobule was incubated for 10 min at 37uC in
the collagenase solution. Using sterile pipettes, the tissue was
gently teased apart to release cells and washed once with Ca2+-free
HEPES buffer at 800 rpm for 30 s at 4uC. The pellet was gently
re-suspended in DMEM, layered on 60% Percoll (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) and centrifuged at 2000 rpm
for 2 min at 4uC. The resulting pellet was re-suspended in
complete culture medium (DMEM supplemented with 10% FCS,
1% penicillin streptomycin, 1% HEPES, and 0.05 mM of b-
mecarptoethanol (b-ME, Sigma-AldrichH), and centrifuged again
at 800 rpm for 30 s at 4uC. The pellet was finally re-suspended
again in 5 ml of DMEM for counting. Viability of isolated
hepatocytes was assessed by light microscopy and trypan blue dye
exclusion. As reported previously [6] hepatocyte contamination
with Kupffer/dendritic cell markers is less than 1% as determined
by FACS analysis [6,10,23,24]. Then, mice were injected iv with
76105 live hepatocytes re-suspended in 200 ml of sterile DMEM.
To obtain infected hepatocytes, 16106 of live or irradiated wt
PbSPZ were injected iv through the tail vein of BALB/c mice. Two
hours later, the liver was removed from the infected mouse and
perfused as described above.





hepatocytes T cell clones
Mice protected/total
injected % of protection p-value
A yes C7 8/8 100 A versus B = 0.006
B yes S14 0/3 0 B versus C = 1
C yes None 1/4 25 A versus C = 0.018
Each recipient TAP2/2 mouse (H-2Kb) received 76105 PbSPZ-infected BALB/c (H-2kd) hepatocytes by IS transfer as described in Materials and Methods. Before IS
injection, infected hepatocytes were isolated from BALB/c mice that were injected (iv) with 106 ANKA wt PbSPZ 2 h earlier. C7 and S14 (20 million cells per mouse, iv)
were injected into the corresponding group 4 h after IS transfer. Mice were protected if they remained parasite negative 2 weeks after infected hepatocyte transfer.
doi:10.1371/journal.pone.0051875.t001
In Vivo Presentation of Antigens by Hepatocytes
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e51875
Intrasplenic (IS) Transfer
Hepatocellular transplantation was carried out by direct
injection of 76105 hepatocytes in 200 ml of sterile DMEM with
a syringe into the splenic parenchyma of recipient mice that were
anaesthetized with Isoflurane (Provet AG, Berne, Switzerland).
Briefly, under aseptic and anaesthesia conditions, cautiously, with
a chisel and a clip, the abdomen of the mouse was opened on the
left flank. Using a clamp fitted, the spleen was gently pulled out
and placed on a sterile piece of paper. The injection of cell
suspension in the spleen parenchyma was carefully carried out at a
rate of 10 ml per 10 respiratory cycles of the mouse. Suturing and
clamping of the skin minimized leakage from the site of operation.
Four hours later, 20 million PbCSP-restricted CD8+ T-cells (C7-
clone) or irrelevant CD8+ T-cells (clone S14) were injected iv
through the tail vein in a volume of 500 ml of DMEM. Control
mice received only hepatocytes.
T-cell Clone Re-stimulation
The C7 and irrelevant S14 clones [3,21] were re-stimulated
weekly, maintained at 37uC and used as effector cells. Briefly,
P815 cells (mastocytoma cells as antigen presenting cells, APC)
were re-suspended (16106 cells/ml) in complete culture medium
(DMEM supplemented with 10% FCS +1% of pyrimethamine-
streptomycin +0.1% of b-ME and 1% of HEPES) and pulsed for
1 hour with PbCSP-epitope peptides (1 mg/ml) specific for C7-and
S14 clones. C7 and S14 were washed and re-suspended (26106/
ml/well) in CTL culture medium (complete culture medium
supplemented by 30 U/ml of mouse IL-2) in a 6-well plate. For re-
stimulation, the respective clones were added to the 16106 pulsed
and irradiated P815 cells (10000 rads/20 minutes) in the presence
of 156106/well of irradiated-BALB/c spleen cells (5000 rads/10
minutes) in 6-well flat bottom plates. In the intrasplenic
experiment, clones were re-stimulated and kept for two weeks in
culture to make sure they were resting at the time of injection.
Cytochrome c Treatment and Induction of CD8+ T-cells
BALB/c mice were depleted of cross-presenting DCs by iv
treatment for 3 days with 15 mg/ml (5 mg/ml per day) of horse
cyt c (Sigma-AldrichH, St Louis, LA) in 100 ml of PBS (GibcoH
InvitrogenTM). Control mice received 100 ml of PBS alone. On the
last day of treatment, mice were immunized iv with 16105 wt
PbiSPZ). Seven-to-ten days later, the frequency of both PE-
conjugated SYIPSAEKI-tetramer and FITC-conjugated anti-
mouse CD8 antibody (BD Biosciences, Allschwil, Switzerland)
specific CD8+ T-cells was measured in different mouse tissues
(blood = PBL, spleen, liver and lymph nodes (LN)) by flow
cytometry.
Real Time PCR (RT-PCR)
In vivo assessment of parasite loads was performed by RT-PCR
as described previously [25]. Briefly, BALB/c mice were injected
iv with 16105 PbiSPZ (wt or spect (2)). Two hours later, total livers
and spleens were isolated, perfused with PBS alone and total RNA
was extracted. Then, cDNA was synthesized using specific primers
Table 2. Specificity of activation of C7 clone and protection.
Treatment
TAP2/2 mouse
group Anka wt SPZ BALB/c hepatocytes C7 clone
Mice protected/total
injected % of protection
A None SPZ infected yes 5/5 100 p-value
B None SPZ infected none 0/5 0 A versus B = 0.008
C Yes Naı¨ve yes 1/7 14 A versus C = 0.015
D Yes none yes 0/3 0 A versus D = 0.018
E Yes none none 0/3 0 A versus E = 0.018
Mice were first injected (iv) or not with 103 live wild-type (wt) ANKA PbSPZ 10 h before they received or not 76105 naı¨ve-BALB/c hepatocytes and C7 clone as indicated
above. Infected hepatocytes were isolated from BALB/c mice injected with 106 ANKA wt PbSPZ 2 h earlier; and naı¨ve BALB/c hepatocytes were isolated from naı¨ve
BALB/c mice. Mice were considered protected if they remained parasite negative 2 weeks after infection.
doi:10.1371/journal.pone.0051875.t002
Table 3. BALB/c mice injected with iSPZ-loaded hepatocytes are protected against SPZ challenge.
2 weeks after challenge
Mouse group (n of SPZ for challenge) Treatment Mice protected/total challenged % of protection p-value: IS versus naive
A (2000) IS 5/5 100 0.167
Naive 2/5 40
B (5000) IS 2/6 33 0.125
Naive 0/10 0
Total IS 7/11 64 0.014
Naive 2/15 13
BALB/c mice were injected (IS transfer) with 76105 PbiSPZ-infected or naı¨ve BALB/c hepatocytes. Infected hepatocytes were obtained from BALB/c mice immunized
with 106 ANKA wt iSPZ 2 h earlier. Recipient mice were then challenged with two different doses (26103 and 56103, respectively, A and B) of live PbSPZ one week later.
Mice were considered protected if they remained parasite negative 2 weeks after challenge.
doi:10.1371/journal.pone.0051875.t003
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for the P. berghei 18S rRNA (forward: 59 AAGCATTAAA-
TAAAGCGAATACATCCTTAC-39 and reverse: 59 GGA-
GATTGGTTTTGAC GTTTATGTG-39) as described previous-
ly [25]. The DNA was thus amplified in the LightCycler 2.0
Instrument (Roche Diagnostics, Basel, Switzerland) using the
program Roche LightCycler Run 5.32, and the relative parasite
DNA load was thus determined in liver and spleen for each type of
SPZ.
Parasitemia Assessment
At different time points after the IS transfer or challenge with
live PbSPZs (iv), parasitemia was assessed by 10% Giemsa (FlukaH,
Sigma-AldrichH)-stained blood smears. Blood smear slides were
air-dried and read by light microscopy (Olympus CH-2, Micro-
scope Company, Hicksville, NY) to determine infected red blood
cells (iRBC). Animals were protected against malaria if they
remained negative in Giemsa-stained blood smears 2 weeks after
receiving infected hepatocytes or live SPZ. Control animals were
included to verify infectivity of SPZ or infected hepatocytes. In
each control animal, parasitemia was detectable 7 days after IS
transfer or challenge.
Statistical Analysis
Different statistic tests were performed using GraphPad Prism
software (version 6). Fisher’s exact test compares the proportion of
mouse protection among various groups. The Mann-Whitney test
was performed to compare parasite DNA load and frequency of
PbCSP-specific CD8+ T-cells in PBL in two independent
experiments or in different organs in the same experiment in
which mice underwent different treatments (wild-type and Spect
(2) iSPZ or PBS and cyt c groups). All p-values equal to or lower
than 0.05 were considered significant.
Figure 1. Level of PbCSP-specific CD8+ T-cells in different organs of BALB/C mice after treatment with either cyt c or PBS and
immunization with PbiSPZ. Two groups of BALB/c mouse were pre-treated (iv through the tail vein) with 5 mg/mouse of cyt c per day for 3 days
in 100 ml of PBS or with 100 ml of PBS alone. Immediately after the last treatment, mice were immunized with 16105 PbiSPZ in 100 ml of RPMI. One-
week later, PbCSP epitope-specific CD8+ T-cell frequency (2 mice per group of treatment) was evaluated in peripheral blood lymphocytes (PBL), liver,
lymph nodes (LN) and spleen. Naı¨ve (receiving neither cyt c, PBS nor iSPZ) mice were used as negative control. Inserted panel shows the fold change
in frequency and the percentage of inhibition of PbCSP-specific CD8+ T-cells in cyt c-treated compared to PBS alone-treated groups.
doi:10.1371/journal.pone.0051875.g001




challenged % of protection
Cyt c 10/10 100
PBS 10/10 100
Naive 1/10 10
Protection of mice after cyt c or PBS treatment from live SPZ challenge of two
independent experiments (5 mice per group in each experiment). Mice were
either pre-treated iv for 3 days with 5 mg/mouse of horse cyt c per day in
100 ml of PBS or with 100 ml of PBS alone. On the last day of treatment, mice
were immunized iv with 16105 PbiSPZ in 100 ml of RPMI. One week later, mice
were challenged with 56103 live PbSPZ. Parasitemia was checked at 1 and 2
weeks after challenge. Mice were considered protected if they remained
parasite negative 2 weeks after challenge.
doi:10.1371/journal.pone.0051875.t004
In Vivo Presentation of Antigens by Hepatocytes
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51875
Results
Infected Hepatocytes Present the PbCSP-specific Epitope
to Cloned CD8+ T-cells with Subsequent Protection
against Malaria
To show that infected hepatocytes process and present PbCSP,
TAP2/2 mice received BALB/c PbSPZ-infected hepatocytes by
IS transfer followed by iv injection of PbCSP specific (clone C7) or
irrelevant (S14 clone) CD8+ T-cells 4 h later. TAP 2/2 mice
were selected to bypass the possibility that presentation could be
performed by professional APCs through processing of apoptotic,
infected hepatocytes or live SPZs possibly externally associated
with BALB/c hepatocytes. In addition, the host vs graft immune
response is minimized. All mice (8/8; 100%) that received infected
hepatocytes and the specific C7 clone were protected from an
infective sporozoite challenge (Table 1, group A). In contrast, all
mice receiving the irrelevant S14 clone were infected (Table 1,
group B). In addition, 75% of naive TAP2/2 mice treated with
infected BALB/c hepatocytes were infected (Table 1, group C).
In order to show that the protective immune response is specific
and not due to a bystander effect or a continuous secretion of
cytokine by the C7 clone, TAP2/2 mice were first infected with
live PbSPZ (1000/mouse in iv) or not. Ten hours later, mice
received infected or naı¨ve BALB/c hepatocytes together or
without C7 clone as indicated in Table 2. Parasitemia determi-
nation of group C showed that only 1/7 (14%) of mice was
protected (Table 2, group C). Other controls showed that
protection occurred only in the group that received infected
BALB/c hepatocyte and C7 clone (Table 2, group A).
Infected Hepatocytes Prime PbCSP-specific CD8+ T-cells
and Protect Mice against SPZ Challenge
Since the infected hepatocytes can reactivate resting CSP-
specific CD8+ T-cells and induce protective immunity (Table 1
and 2), the next step was to determine if they could also prime
naı¨ve T-cells to protect mice against live SPZ challenge. To this
effect, we injected iSPZ-infected BALB/c hepatocytes into naive
BALB/c mice before challenging with live SPZ. Considering that
the immunization procedure may give rise to a sub-optimal
immunity (about 700 infected hepatocytes injected IS if the overall
infection efficacy is estimated to be 10%), mice were challenged
with a sub-optimal or optimal dose of live SPZ (26103 and 56103)
that led to 60% and 100% infection in naı¨ve mice, respectively,
with an overall protection of 13% (Table 3). In contrast, mice
receiving iSPZ-infected hepatocytes were protected at 64% (7/11;
p = 0.014) (Table 3), suggesting that the infected hepatocytes
could contribute to the priming of naı¨ve T-cells and protection of
mice against infection.
To further corroborate that hepatocytes could prime naı¨ve T-
cells and induce protection, BALB/c mice were treated with cyt c
to delete cross-presenting DCs before and during iSPZ immuni-
zation. This protocol was established according to previous studies
which showed that cross-presenting DCs can be largely depleted
after in vivo cyt c treatment [16,26]. The first experiment (as pilot)
showed a significant reduction of 60% of PbCSP245–253 specific
CD8+ T-cells in PBL after cyt c treatment (data not shown). In the
second experiment, the analysis was extended to other organs (LN,
spleen and liver) (Fig. 1). Thus, FACS analysis showed that
induction of PbCSP-specific CD8+ T-cells was highly reduced in
the cyt c- compared to the PBS -treated mice in PBL and liver
(86% and 67%, respectively), while this reduction was about 50%
Figure 2. Relative comparative wt and spect (2) parasite DNA load in spleen and liver of immunized mice. To compare relative load of
wt and spect (2) parasite DNA in liver and spleen, BALB/c (3 mice per group) were immunized iv on tail with 16105 iSPZ (wt or spect (2)) in 500 ml of
RPMI. Two hours later, a real-time PCR was performed following extraction of respective parasite RNA. Every sample was done in duplicate. To avoid
any contamination by eventual parasite from blood, the liver and spleen were perfused with PBS before performing the RT-PCR. Figures a and b
represent wt and spect (2) parasite DNA load, respectively, in the liver and spleen 2 h after iSPZ injection (iv). Naı¨ve mice (receiving only 500 ml iv of
DMEM) were used as a control.
doi:10.1371/journal.pone.0051875.g002
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in LN and spleen (Fig. 1, inserted panel). Taking the PBL data
from the two experiments or from all organs in the second
experiment, normalizing and combining them, we obtained p
values of 0.003 (PBL) and 0.001 (organs) for the cyt c-treated
compared to PBS groups. In spite of these differences, both groups
were protected after SPZ challenge (Table 4).
Protective Immune Response Induced in BALB/c Mice
Immunized with spect (2) iSPZ
Wild-type SPZs are known to be able to cross several cells
(leaving a trail of the CSP behind) before infecting a single
hepatocyte, unlike spect (2) SPZ that infect hepatocytes without
cell traversal. It has been shown that both infected and traversed
hepatocytes are able to process and present PbSPZ CSP to primed
CD8+ T-cells to induce IFN-c secretion in vitro but only the
infected hepatocytes were responsible for their own elimination
[6,20]. Similar experiments were then performed in vivo. Thus, it
was expected that spect (2) SPZ would activate a lower number of
the PbCSP-specific CD8+ T-cells in the periphery and present a
lower parasite load in the liver. RT-PCR clearly showed that the
relative parasite DNA load in liver and spleen was significantly
higher in mice receiving wt iSPZ compared to the spect (2) iSPZ
parasite group (p = 0.026 and 0.008, respectively) (Fig. 2a and b).
In addition, FACS analysis showed that the level of the PbCSP-
specific CD8+ T-cell response was significantly higher in the wt
compared to the spect (2) group in PBL and spleen (p = 0.029)
suggesting a role of cross-presenting DCs in these compartments
(Fig. 3). In contrast, in the liver, the frequency of CD8+ T-cells
was similar (p = 0.886) for the two kinds of iSPZ (Fig. 3) in spite
of a lower parasite load for spect (2). Both groups of mice were
protected against live SPZ challenge (Table 5). Together, these
data indicate that T-cell traversal by SPZ induces a higher level of
immune response in PBL and spleen, but not in the liver, further
Figure 3. Frequency of PbCSP-specific CD8+ T-cells in different organs of BALB/c mice immunized with wt or spect (2) iSPZ. BALB/c
mice (4 mice per group) were immunized (iv) with wt or spect (2) ANKA PbiSPZ (one dose of 16105 iSPZ). Seven (7) days later, PBL, liver and spleen
cells of mice were isolated to determine frequency of PbCSP-specific CD8+ T-cells by flow cytometry (FACScan). The CD8+ T-cells were double stained
with PE-conjugated PbCSP epitope tetramer and FITC-conjugated anti-mouse CD8b antibody. The naive group received neither wt nor spect (2) iSPZ.
p-value compares statistically significant mean of CD8+ T-cell frequency between wt and spect (2) iSPZ-immunized groups.
doi:10.1371/journal.pone.0051875.g003
Table 5. Both wt and spect (2) PbiSPZ immunization protect mice against SPZ challenge.
Immunization (number of PbISPZ) Challenge with PbSPZ Mice protected/total challenged % of protection
Wild-type (16105) 16104 5/5 100
Spect (2) (16105) 16104 5/5 100
Naive (0) 16104 0/5 0
One week after 16105 PbiSPZ (wt or spect (2)) immunization, BALB/c mice were challenged with 16104 live ANKA wt PbSPZ. Parasitemia was checked at 1 week and 2
weeks post challenge and mice were considered protected when they remained parasite negative 2 weeks after challenge.
doi:10.1371/journal.pone.0051875.t005
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supporting the key role of infected hepatocytes in antigen
presentation and induction of protective immunity.
Discussion
Data presented in this manuscript provide further evidence for
the role of Plasmodium infected hepatocytes in the stimulation of
protective secondary CD8+ T-cells leading to the elimination of P.
berghei pre-erythrocytic stages. In addition, they indicate that
hepatocytes can indeed prime sporozoite-specific, protective naı¨ve
T-cells. While the antigen-presenting role of infected hepatocytes
in the secondary CD8+ T-cell response seems to be accepted, the
mode of priming naı¨ve CD8+ T-cells is still, in our opinion, not yet
established. With regard to the first point, the in vivo data
presented here are fully consistent with our previous in vitro results
[6,20] and with in vivo data published by Zavala and collaborators
[7] via bone marrow cell transfer experiments. In our case, we
transferred either BALB/c infected hepatocytes or a CS specific T-
cell clone or both to TAP-deficient H-2kb mice. Tap2/2mice
were chosen to bypass the possibility that antigen presentation is
mediated by professional antigen presenting cells which might
have ingested apoptotic infected hepatocytes [8] or live sporozoites
possibly externally associated with BALB/c hepatocytes, and
minimize host vs graft immune responses. In addition, we have
determined protection as lack of infection in mice 14 days post-
challenge, which represents a stringent, but the only significant
standard for protection for pre-erythrocytic vaccines. Our results
show that protection from infection is antigen-specific since mice
are not protected if an irrelevant CD8+ T-cell clone is used. In
addition, as observed in vitro [6], our results indicate that infected
hepatocytes are directly killed by the antigen- specific T cells and
not by a bystander effect through continuous secretion of IFN-c or
other lymphokines by the injected T-cell clones or host vs graft
immune response since concomitant infection of TAP-deficient
mice does not lead to protection after treatment with the CS
specific T-cell clone and/or naı¨ve BALB/c hepatocytes. These
and the previous data [6,7] clearly establish the central role of
infected hepatocytes in the total clearance of Plasmodium infection
in vivo once an immune response has been induced (secondary
response). However, in our opinion, the role of hepatocytes in
priming naı¨ve, T-cells is not yet elucidated. Zavala and
collaborators [7,16] claim that peripheral dendritic cells prime
CD8+ T-cells, while Leiriao et al. [8] suggest that apoptotic
infected hepatocytes provide antigens to liver dendritic cells. In
addition, these claims seem to be supported by the notion that
hepatocytes act as tolerizing cells [27,28]. On the other hand,
given the large number of hepatocyte genes affected by sporozoites
and salivary gland components, including some related to antigen
processing and presentation and chemokine production it is not far
fetched to hypothesize that infected hepatocytes become full-
fledged antigen presenting cells upon infection [29,30]. This would
allow the activation of T-cells specific to sporozoite and late liver
stage antigens (14). This would optimize the balance between
infection and immune responses that parasites and hosts have
developed through co-evolution. Evidence that the liver is central
to obtaining an optimal immune response was provided early on
by Renia et al [10] in which similar results as obtained here were
presented, where immunization with non-parenchymal cells did
not result in protection. Recent data by Epstein et al. [12] in which
a better immune response was obtained by immunization of mice
with irradiated sporozoites via iv than id or sc injection also point
to the antigen-presenting role of the liver. In this study, we
specifically target the role of infected hepatocytes in the immune
response by immunizing (iv) mice with spect (2) iSPZ that infect
hepatocytes without prior traversal. We show that, in spite of a
significant decrease in parasite DNA load, the liver CSP-specific
CD8+ T-cell response was similar to that in wt iSPZ-immunized
groups. This and cyt c treatment of mice prior to immunization
with iSPZs further support the key role of infected hepatocytes in
T-cell priming to provide protective immune responses.
In conclusion, the data provided show that hepatocytes can
indeed present Plasmodium berghei CSP epitopes to primed CD8+ T-
cells and strongly suggest that they could also prime parasite-
specific naı¨ve T-cells to fully protect mice against a live parasite
challenge. But in our opinion, formal proof of the role of
hepatocytes in antigen presentation can only be obtained by
isolating malaria parasite infected hepatocytes for in vivo and
in vitro experiments.
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